Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide for aggressive pituitary tumours
ACTRN12610000738022Phase 2Completed
- Sponsor
- Ann McCormack
- Start
- Oct 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in pituitary neoplasm, sponsored by Ann McCormack. Primary endpoint: Progression-free survival. Started Oct 2010; status: completed.
02
Drugs
temozolomide
03
Conditions
pituitary neoplasm
Beyond the preview
Go deeper on ACTRN12610000738022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000738022.